Clinical Trials Directory

Trials / No Longer Available

No Longer AvailableNCT04903613

Global Managed Access Program Cohort for Ligelizumab in CSU

Global Managed Access Program (MAP) Cohort to Provide Access to Ligelizumab (QGE031) for Chronic Spontaneous Urticaria (CSU).

Status
No Longer Available
Phase
—
Study type
Expanded Access
Enrollment
—
Sponsor
Novartis Pharmaceuticals · Industry
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

Global Cohort Managed Access Program (MAP) to provide access to ligelizumab (QGE031) for chronic spontaneous urticaria (CSU)

Conditions

Interventions

TypeNameDescription
DRUGLigelizumabLigelizumab 120 mg s.c every 4 weeks

Timeline

First posted
2021-05-26
Last updated
2022-05-11

Source: ClinicalTrials.gov record NCT04903613. Inclusion in this directory is not an endorsement.

Global Managed Access Program Cohort for Ligelizumab in CSU (NCT04903613) · Clinical Trials Directory